# ACI-7104 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aci-7104

> ACI-7104, sponsored by AC Immune SA (ACIU): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ACI-7104 |
| Codes | ACI-7104 |
| Sponsor | AC Immune SA (ACIU) https://sec-api.dev/companies/aciu/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2025-04-30, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090704): "The VacSYn trial commenced in July 2023 with the dosing of the first patient and is progressing well with over 30 patients randomized in Part 1 of the study." https://www.sec.gov/Archives/edgar/data/1651625/000110465926090704/aciu-20260630xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105896): "The VacSYn trial commenced in July 2023 with the dosing of the first patient and is progressing well with over 30 patients randomized in Part 1 of the study." https://www.sec.gov/Archives/edgar/data/1651625/000110465925105896/aciu-20251104xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010174): "The VacSYn trial commenced in July 2023 with the dosing of the first patient and is progressing well with over 30 patients randomized in Part 1 of the study." https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-005922): "The VacSYn trial commenced in July 2023 with the dosing of the first patient and is progressing well with over 30 patients randomized in Part 1 of the study." https://www.sec.gov/Archives/edgar/data/1651625/000155837025005922/aciu-20250430xex99d2.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-13, last confirmed 2025-08-05.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-005922): "Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1651625/000155837025005922/aciu-20250430xex99d3.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010174): "Further interim results from Part 1 of the VacSYn trial of ACI-7104.056 are expected later this year, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment around year end, with interim results thereafter." https://www.sec.gov/Archives/edgar/data/1651625/000155837025010174/aciu-20250630xex99d3.htm
- SEC Form 10-K (accession 0001558370-25-002855): "Further interim results, including pharmacodynamic data, are expected in H1 2025." https://www.sec.gov/Archives/edgar/data/1651625/000155837025002855/aciu-20241231x20f.htm

### late 2025: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-04-30, last confirmed 2025-04-30.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-005922): "o Based on further interim results to be reported later in 2025, including pharmacodynamic and biomarker data, AC Immune may decide to initiate Part 2 of VacSYn, with the aim of establishing early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study." https://www.sec.gov/Archives/edgar/data/1651625/000155837025005922/aciu-20250430xex99d2.htm

### Dec 2025: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2026-06-11, last confirmed 2026-06-11.
- Press release filed with the SEC (EX-99) (accession 0000950103-26-008815): "Positive interim results from the Phase 2 VacSYn trial of ACI-7104 in early PD were reported in December 2025." https://www.sec.gov/Archives/edgar/data/1651625/000095010326008815/dp248283_exh9901.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aci-7104.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACI-7104 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aci-7104

```bibtex
@misc{secapidev_pdufa_aci_7104_20261116,
  title        = {ACI-7104 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aci-7104}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aci_7104_20261116","title":"ACI-7104 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aci-7104","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
